We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Interactive Video Gaming Device Could Aid MS Patients

By LabMedica International staff writers
Posted on 23 Aug 2016
A commonly used 3D depth-sensing camera could become a low-cost means of monitoring treatment effectiveness for walking difficulties of patients with gait-impairing diseases such as multiple sclerosis (MS).

The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. More...
A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).

In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.

Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.

Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.

The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.

Related Links:
McGill University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.